Prostate Adenocarcinoma — Variants & evidence

Prostate Adenocarcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MTHFR A222V1
(predisposing)	Predisposing	B	Supports Protectiveness	4	accepted	EID1756 Study of 1817 prostate adenocarcinoma cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of prostate cancer risk in a population of Han Chinese in Shang… (full text at CIViC) PMID 27819322 · Wu et al., 2016 · Open in CIViC	civic
PTEN Deletion1
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID505 In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those witho… (full text at CIViC) PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC	civic
PTEN Mutation1
Alpelisib + Enzalutamide + PI3Kbeta Inhibitor AZD8186Combination	Predictive	D	Supports Sensitivity Response	3	accepted	EID1522 Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100). Mice treated … (full text at CIViC) PMID 25544636 · Schwartz et al., 2015 · Open in CIViC	civic

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.